{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:52Z","timestamp":1792801792236,"version":"4.5.0"},"reference-count":81,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CDMRP, Breast Cancer Research Program","award":["W81XWH2010045"],"award-info":[{"award-number":["W81XWH2010045"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Targeting the interleukin-6 (IL-6)\/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopausal osteoporosis, when combined with conjugated estrogens in Duavee, also has a novel function as an inhibitor of IL-6\/GP130 interaction. BZA is currently under investigation for its potential anticancer therapeutic function through the inhibition of the IL-6\/GP130 pathway. Numerous studies have highlighted the efficacy of BZA (monotherapy or combined with other chemotherapy drugs) in impeding progression across multiple cancers. In this review, we mainly focus on the anticancer activity of BZA and the underlying anticancer mechanism through inhibition of the IL-6\/GP130 pathway, aiming to provide valuable insights for the design and execution of further research and the potential repositioning of BZA in oncological clinical trials.<\/jats:p>","DOI":"10.3390\/curroncol31100426","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T09:16:10Z","timestamp":1727428570000},"page":"5737-5751","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6\/GP130 Signaling"],"prefix":"10.3390","volume":"31","author":[{"given":"Changyou","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Bopp","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Wen","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, McGovern Medical School, University of Texas Health, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tkaczuk","sequence":"additional","affiliation":[{"name":"Marlene and Stewart Greenebaum Cancer Center, School of Medicine, University of Maryland, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5618-8781","authenticated-orcid":false,"given":"Jiayuh","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1042\/BST20180136","article-title":"The role of the interleukin (IL)-6\/IL-6 receptor axis in cancer","volume":"46","author":"Taher","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/bab.2150","article-title":"A comprehensive review on anticancer mechanism of bazedoxifene","volume":"69","author":"Zafar","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ra\u0161kov\u00e1, M., Lacina, L., Kej\u00edk, Z., Venhauerov\u00e1, A., Skali\u010dkov\u00e1, M., Kol\u00e1\u0159, M., Jakubek, M., Rosel, D., Smetana, K., and Br\u00e1bek, J. (2022). The role of IL-6 in cancer cell invasiveness and metastasis-overview and therapeutic opportunities. Cells, 11.","DOI":"10.3390\/cells11223698"},{"key":"ref_5","first-page":"13","article-title":"Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-\u03b1-positive breast cancer","volume":"3","author":"Casneuf","year":"2016","journal-title":"Breast Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1111\/jcpt.13781","article-title":"Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential","volume":"47","author":"Ghasemi","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3892\/ol.2015.3019","article-title":"Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells","volume":"9","author":"Kim","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1021\/jm401144z","article-title":"Drug design targeting protein\u2013protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: Discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6\/GP130 interface","volume":"57","author":"Li","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbrc.2017.07.067","article-title":"Inhibition of IL-6\/STAT3 signaling in human cancer cells using Evista","volume":"491","author":"Shi","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-019-05183-2","article-title":"Bazedoxifene is a novel IL-6\/GP130 inhibitor for treating triple-negative breast cancer","volume":"175","author":"Tian","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-09-2468","article-title":"Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res."},{"key":"ref_12","first-page":"2849","article-title":"2-Phenylnaphthyridin-4-one derivative LYF-11 inhibits interleukin-6-mediated epithelial\u2013to\u2013Mesenchymal transition via the inhibition of JAK2\/STAT3 signaling pathway in MCF-7 cells","volume":"38","author":"Liu","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1574884711308020006","article-title":"The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice","volume":"8","author":"Maximov","year":"2013","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/mol.111.072249","article-title":"The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor \u03b1 and cyclin D1","volume":"80","author":"Kim","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.ejca.2005.08.016","article-title":"The role of IL-6 and STAT3 in inflammation and cancer","volume":"41","author":"Hodge","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","article-title":"The wolf in sheep\u2019s clothing: The role of interleukin-6 in immunity, inflammation and cancer","volume":"14","author":"Naugler","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-4598-12-26","article-title":"IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus","volume":"12","author":"Chen","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nature07475","article-title":"Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours","volume":"457","author":"Rebouissou","year":"2009","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1535-7163.MCT-12-1082","article-title":"Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Mol","volume":"12","author":"Xu","year":"2013","journal-title":"Cancer Ther."},{"key":"ref_23","first-page":"37","article-title":"Signal transduction through homo-or heterodimers of gp130","volume":"12","author":"Kishimoto","year":"1994","journal-title":"Stem Cells"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1126\/science.8511589","article-title":"IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase","volume":"260","author":"Murakami","year":"1993","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1073\/pnas.91.6.2285","article-title":"Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130","volume":"91","author":"Narazaki","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/bcr1680","article-title":"Stat3 is tyrosine-phosphorylated through the interleukin-6\/glycoprotein 130\/Janus kinase pathway in breast cancer","volume":"9","author":"Berishaj","year":"2007","journal-title":"Breast Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197907","DOI":"10.1016\/j.virusres.2020.197907","article-title":"IL-6\/STAT3 mediates the HPV18 E6\/E7 stimulated upregulation of MALAT1 gene in cervical cancer HeLa cells","volume":"281","author":"Hao","year":"2020","journal-title":"Virus Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wu, C.J., Sundararajan, V., Sheu, B.C., Huang, R.Y., and Wei, L.H. (2019). Activation of STAT3 and STAT5 signaling in epithelial ovarian cancer progression: Mechanism and therapeutic opportunity. Cancers, 12.","DOI":"10.3390\/cancers12010024"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1074\/jbc.271.11.5961","article-title":"Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction","volume":"271","author":"Kaptein","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1074-7613(00)80501-4","article-title":"Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis","volume":"5","author":"Fukada","year":"1996","journal-title":"Immunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1158\/0008-5472.CAN-05-2203","article-title":"Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3","volume":"66","author":"Leslie","year":"2006","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.18632\/oncotarget.3540","article-title":"Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/sj.onc.1203476","article-title":"The role of STATs in transcriptional control and their impact on cellular function","volume":"19","author":"Bromberg","year":"2000","journal-title":"Oncogene"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","article-title":"STAT proteins: Novel molecular targets for cancer drug discovery","volume":"19","author":"Turkson","year":"2000","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/sj.onc.1206226","article-title":"Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway","volume":"22","author":"Wei","year":"2003","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-04-1752","article-title":"Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells","volume":"12","author":"Gritsko","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Chen, C.L., Loy, A., Cen, L., Chan, C., Hsieh, F.C., Cheng, G., Wu, B., Qualman, S.J., Kunisada, K., and Yamauchi-Takihara, K. (2007). Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-111"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1349-7006.2011.01932.x","article-title":"Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells","volume":"102","author":"Liu","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.18632\/oncotarget.930","article-title":"Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In Vitro and In Vivo","volume":"4","author":"Yan","year":"2013","journal-title":"Oncotarget"},{"key":"ref_41","first-page":"135","article-title":"Conjugated estrogen\/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause","volume":"10","author":"Mirkin","year":"2014","journal-title":"Women\u2019s Health"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1759720X11422602","article-title":"Bazedoxifene: The evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis","volume":"4","author":"Komm","year":"2012","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1525-1438.2007.01025.x","article-title":"The risk of developing uterine sarcoma after tamoxifen use","volume":"18","author":"Lavie","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/gme.0b013e3181a818db","article-title":"Bazedoxifene, a selective estrogen receptor modulator: Effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women","volume":"16","author":"Archer","year":"2009","journal-title":"Menopause"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/GME.0000000000000419","article-title":"A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: Effects on bone density and fracture","volume":"22","author":"Palacios","year":"2015","journal-title":"Menopause"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e37161","DOI":"10.7554\/eLife.37161","article-title":"The SERM\/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells","volume":"7","author":"Fanning","year":"2018","journal-title":"Elife"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2019.01.026","article-title":"Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer","volume":"448","author":"Fu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/1568009615666150916093110","article-title":"Persistent GP130\/STAT3 signaling contributes to the resistance of doxorubicin, cisplatin, and MEK inhibitor in human rhabdomyosarcoma cells","volume":"16","author":"Wu","year":"2016","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1568009618666180430123939","article-title":"Blocking IL-6\/GP130 signaling inhibits cell viability\/proliferation, glycolysis, and colony forming activity in human pancreatic cancer cells","volume":"19","author":"Chen","year":"2019","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1758835920940939","DOI":"10.1177\/1758835920940939","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer","volume":"12","author":"Blonz","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dillon, M., Lopez, A., Lin, E., Sales, D., Perets, R., and Jain, P. (2021). Progress on Ras\/MAPK Signaling Research and Targeting in Blood and Solid Cancers. Cancers, 13.","DOI":"10.3390\/cancers13205059"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e9539","DOI":"10.15252\/emmm.201809539","article-title":"Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth","volume":"11","author":"Thilakasiri","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","article-title":"Epithelial\u2013mesenchymal transitions in tumor progression","volume":"2","author":"Thiery","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: A leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7150\/jca.38350","article-title":"Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo\/YAP pathway","volume":"11","author":"Fu","year":"2020","journal-title":"J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Kim, L., Park, S.A., Park, H., Kim, H., and Heo, T.H. (2021). Bazedoxifene, a GP130 inhibitor, modulates EMT signaling and exhibits antitumor effects in HPV-positive cervical cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168693"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13046-019-1072-8","article-title":"Bazedoxifene as a novel GP130 inhibitor for Colon Cancer therapy","volume":"38","author":"Wei","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-15-0921","article-title":"Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapy","volume":"15","author":"Wu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/cas.13940","article-title":"Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6\/glycoprotein 130\/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma","volume":"110","author":"Ma","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3892\/or.2022.8263","article-title":"Inhibition of GP130\/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer","volume":"47","author":"Park","year":"2022","journal-title":"Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.freeradbiomed.2023.01.004","article-title":"Bazedoxifene-induced ROS promote mitochondrial dysfunction and enhance osimertinib sensitivity by inhibiting the p-STAT3\/SOCS3 and KEAP1\/NRF2 pathways in non-small cell lung cancer","volume":"196","author":"Meng","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Xiao, H., Bid, H.K., Chen, X., Wu, X., Wei, J., Bian, Y., Zhao, C., Li, H., Li, C., and Lin, J. (2017). Repositioning Bazedoxifene as a novel IL-6\/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180297"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Mayrovitz, H.N. (2022). Subtypes of Breast Cancer. Breast Cancer, Exon Publications.","DOI":"10.36255\/exon-publications-breast-cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: Biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1373\/clinchem.2009.125377","article-title":"Understanding Resistance to Tamoxifen in Hormone Receptor\u2013Positive Breast Cancer","volume":"55","author":"Higgins","year":"2009","journal-title":"Clin. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"CMO-S18006","DOI":"10.4137\/CMO.S18006","article-title":"Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information","volume":"8","author":"Inic","year":"2014","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.breast.2013.11.011","article-title":"Treatment of HER2-positive breast cancer","volume":"23","author":"Jelovac","year":"2014","journal-title":"Breast"},{"key":"ref_69","first-page":"511","article-title":"Update on triple-negative breast cancer: Prognosis and management strategies","volume":"24","author":"Brouckaert","year":"2012","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: A review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"ref_73","first-page":"1322","article-title":"Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase","volume":"6","author":"Salonga","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s10495-018-1460-0","article-title":"Down-regulating IL-6\/GP130 targets improved the antitumor effects of 5-fluorouracil in colon cancer","volume":"23","author":"Li","year":"2018","journal-title":"Apoptosis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.21873\/anticanres.15003","article-title":"Synergistic effect of bazedoxifene and PARP inhibitor in the treatment of ovarian cancer regardless of BRCA mutation","volume":"41","author":"Zhang","year":"2021","journal-title":"Anticancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MPH.0000000000002782","article-title":"Bazedoxifene suppresses the growth of osteosarcoma cells by inhibiting IL-6 and IL-11\/GP130 Signaling Pathway","volume":"46","author":"Wu","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2016.06.005","article-title":"Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer","volume":"142","author":"Hijaz","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1940-6207.CAPR-19-0315","article-title":"Effect of bazedoxifene and conjugated estrogen (Duavee) on breast cancer risk biomarkers in high-risk women: A pilot study","volume":"12","author":"Fabian","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1158\/1078-0432.CCR-22-2305","article-title":"Clinical efficacy and whole-exome sequencing of liquid biopsies in a phase IB\/II study of bazedoxifene and palbociclib in advanced hormone receptor-positive breast cancer","volume":"28","author":"Tsuji","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/10\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:10Z","timestamp":1760112130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/10\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["curroncol31100426"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31100426","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,25]]}}}